Virpax announces completion of pre-IND meeting for its intranasal enkephalin

Virpax Pharmaceuticals has announced the successful completion of a pre-IND meeting with the FDA regarding the company’s NES100 intranasal enkephalin formulation for the management of acute and chronic pain. NES100 is a molecular envelope technology (MET) formulation licensed from Nanomerics and is delivered via a cartridge-based device.

In January 2020, Virpax announced that it also planned to develop intranasal enkephalin for the treatment of post traumatic stress disorder (PTSD).  

Virpax Chairman and CEO Anthony P. Mack commented, “We are very pleased with the outcome of the pre-IND meeting with the FDA. The initial pathway to move forward with the development of NES100 has been clarified and confirmed.”

Read the Virpax Pharmaceuticals press release.